DB00709ApprovedInvestigationalSmall moleculeHepatitis B Virus Nucleoside Analog Reverse Transcriptase InhibitorHuman Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase InhibitorNucleoside and Nucleotide Reverse Transcriptase Inhibitors
Lamivudine is a reverse transcriptase inhibitor used to treat HIV and hepatitis B infections. A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring.
- Mechanism
- Curator reviewed
Lamivudine is a synthetic nucleoside analogue and is phosphorylated intracellularly to its active 5'-triphosphate metabolite, lamivudine triphosphate (L-TP). This nucleoside analogue is incorporated into viral DNA by HIV reverse transcriptase and HBV polymerase, resulting in DNA chain termination.
- Primary indication
- Lamivudine is indicated in combination with other antiretrovirals the treatment of HIV infection and chronic hepatitis B (HBV).Curator reviewed · 5 structured indications
- Formula / weight
- C8H11N3O3S · 229.256 g/mol (avg)
- First approval
- Canada, 2012 · United States, 1995 · European Union, 2016
- Code names
- BCH 189, (-)- · GR-109714X
- Brand names
Resolves to
Structure
InChIKey
JTEGQNOMFQHVDC-NKWVEPMBSA-NSMILESNC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1What you can answer from here — as of September 23, 2026
4Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
10TransportersSubstrate / inhibitor direction, not just membershipListed above
Which drugs share a target with Lamivudine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account